Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening

BMC Genomics

Volumn 17, Issue 1, 2016, Pages

  Kiessling, Michael K ^a   Schuierer, Sven ^b   Stertz, Silke ^c   Beibel, Martin ^b   Bergling, Sebastian ^b   Knehr, Judith ^b   Carbone, Walter ^b   de Vallière, Cheryl ^a   Tchinda, Joelle ^a   Bouwmeester, Tewis ^b   Seuwen, Klaus ^b   Rogler, Gerhard ^a   Roma, Guglielmo ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Driver mutations; Dropout; EGFR; Kinase; Negative selection; NRAS; Whole genome CRISPR screen

Indexed keywords

CASPASE 9; CRISPR ASSOCIATED PROTEIN; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; GUIDE RNA; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE; TBK1 PROTEIN, HUMAN; TRIB2 PROTEIN, HUMAN;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; DNA REPLICATION; DRUG SENSITIVITY; EXON; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; GENOME-WIDE ASSOCIATION STUDY; HUMAN; LUNG CANCER CELL LINE; MUTAGENESIS; NEUROBLASTOMA CELL LINE; ONCOGENE N RAS; PURIFYING SELECTION; RNA SPLICING; CELL TRANSFORMATION; CRISPR CAS SYSTEM; DRUG EFFECTS; DRUG SCREENING; GENE INACTIVATION; GENETICS; METABOLISM; MUTATION; ONCOGENE; PHENOTYPE; TUMOR CELL LINE;

CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CRISPR-CAS SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE KNOCKOUT TECHNIQUES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MUTATION; ONCOGENES; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RNA, GUIDE;

EID: 84986586549     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-016-3042-2     Document Type: Article

References (32)

1. Chen S, et al. Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160:1246-60.
2. Cong L, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819-23.
3. Hart T, et al. High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities. Cell. 2015;163(6):1515-26.
4. Koike-Yusa H, Li Y, Tan EP, Velasco-Herrera Mdel C, Yusa K. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library. Nat Biotechnol. 2014;32:267-73.
5. Shalem O, et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343:84-7.
6. Wang T, et al. Identification and characterization of essential genes in the human genome. Science. 2015;350:1096-101.
7. Wang T, Wei JJ, Sabatini DM, Lander ES. Genetic screens in human cells using the CRISPR-Cas9 system. Science. 2014;343:80-4.
8. Jinek M, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337:816-21.
9. Mali P, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823-6.
10. Parnas O. et al. A Genome-wide CRISPR Screen in Primary Immune Cells to Dissect Regulatory Networks. Cell. 2015;162(3):675-86.
11. Shi J. et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015;33(6):661-7.
12. Kiessling MK. et al. Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma. PLoS One. 2016;11(1):e0147682.
13. Vujic I, et al. Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies. Oncotarget. 2014;5:7936-44.
14. Amann J, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005;65:226-35.
15. Gilbert LA, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell. 2014;159:647-61.
16. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-50.
17. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761-74.
18. Konig R, et al. A probability-based approach for the analysis of large-scale RNAi screens. Nat Methods. 2007;4:847-9.
19. Barbie DA, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108-12.
20. Aguirre AJ, et al. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016;6:914-29.
21. Munoz DM, et al. CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions. Cancer Discov. 2016;6:900-13.
22. Tym JE, et al. canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic Acids Res. 2016;44:D938-43.
23. Ascierto PA, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14:249-56.
24. Barbie TU, et al. Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth. J Clin Invest. 2014;124:5411-23.
25. Blomen VA, et al. Gene essentiality and synthetic lethality in haploid human cells. Science. 2015;350:1092-6.
26. Moore JD. The impact of CRISPR-Cas9 on target identification and validation. Drug Discov Today. 2015;20:450-7.
27. Barch MJ, Knutsen T, Spurbeck JL. The AGT Cytogenetics Laboratory Manual. 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 1997.
28. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357-9.
29. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010;11:R106.
30. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298:1912-34.
31. Cunningham F, et al. Ensembl 2015. Nucleic Acids Res. 2015;43:D662-9.
32. Schuierer S, Roma G. The exon quantification pipeline (EQP): a comprehensive approach to the quantification of gene, exon and junction expression from RNA-seq data. Nucleic Acids Res. 2016. [Epub ahead of print] PubMed PMID: 27302131.